Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticancer strategies targeting HIF-1.

Eun-Jin Yeo1, Yang-Sook Chun, Jong-Wan Park

  • 1Department of Pharmacology, College of Medicine, Seoul National University, 28 Yongon-dong, Chongno-gu, 110-799, Republic of Korea.

Biochemical Pharmacology
|August 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time-averaged simulated microgravity ameliorates tau-induced deficit in Drosophila melanogaster.

NPJ microgravity·2026
Same author

ADSC-Derived CCL8 Regulates HIF-1α Signaling and Promotes Colorectal Cancer Progression in a 3D Coculture Platform.

Cancer science·2026
Same author

Bilirubin reduces mortality in sepsis models by inhibiting NOX2-mediated formation of neutrophil extracellular traps.

Redox report : communications in free radical research·2026
Same author

A tissue-penetrably engineered deoxyribonuclease 1 to prevent nasal polyp formation in chronic rhinosinusitis.

BMC pharmacology & toxicology·2025
Same author

Cancer Manipulates Adjacent Adipose Tissue to Exploit Fatty Acids via HIF-1α/CCL2/PPARα Axis: A Metabolic Circuit to Support Tumor Progression.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Comprehensive understanding of context-specific functions of PHF2 in lipid metabolic tissues.

Scientific reports·2025
Same journal

Methylated SNHG3 lncRNA counteracts PSMD4-inhibited angiogenesis by HnRNPA2B1 SUMOylation in peripheral arterial disease.

Biochemical pharmacology·2026
Same journal

The organelle-targeting duality of nanomaterials: physicochemical property-guided therapeutic effects and toxicological outcomes.

Biochemical pharmacology·2026
Same journal

The central role of endoplasmic reticulum stress in Parkinson's disease and targeted therapeutic strategies.

Biochemical pharmacology·2026
Same journal

Mechanisms involved in the regulation of carbohydrate and lipid metabolism by oleanane-type pentacyclic triterpenes.

Biochemical pharmacology·2026
Same journal

Myricitrin alleviates paraquat-induced acute lung injury via PERK pathway to attenuate endoplasmic reticulum stress and mitochondrial dysfunction.

Biochemical pharmacology·2026
Same journal

Design, synthesis, and biological evaluation of Combretastatin A4 dimers for the treatment of hepatocellular carcinoma.

Biochemical pharmacology·2026
See all related articles

Hypoxia-inducible factor-1 (HIF-1) drives tumor growth. Inhibiting HIF-1, like with the compound YC-1, shows promise for developing new anticancer therapies with reduced toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Hypoxia-inducible factor-1 (HIF-1) is upregulated in human tumors.
  • HIF-1 promotes tumor progression via genes regulating metabolism, angiogenesis, survival, invasion, and drug resistance.
  • Inhibiting HIF-1 is a potential cancer treatment strategy.

Purpose of the Study:

  • To review the potential of HIF-1 as an anticancer target.
  • To discuss strategies for inhibiting HIF-1 activity.
  • To introduce YC-1 as a novel HIF-1 inhibitor for cancer therapy.

Main Methods:

  • Review of existing literature on HIF-1 and anticancer agents.
  • Analysis of studies investigating YC-1's effects on HIF-1 activity and cancer cells.
  • Evaluation of YC-1's efficacy and toxicity in preclinical models.

Related Experiment Videos

Main Results:

  • YC-1 suppresses HIF-1 activity and vascular endothelial growth factor expression in cancer cells.
  • YC-1 demonstrated tumor growth inhibition in immunodeficient mice.
  • YC-1 treatment showed no significant toxicity during the study period.

Conclusions:

  • HIF-1 is a viable molecular target for anticancer drug development.
  • YC-1 exhibits promising anti-HIF-1 and anticancer properties.
  • YC-1 serves as a lead compound for developing novel HIF-1-targeting anticancer agents.